Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...

Martínez-Castellanos and colleagues evaluated ocular function, neurodevelopment, and growth in infants treated with intravitreal bevacizumab injections for retinopathy of prematurity (ROP) during a ...

Please provide your email address to receive an email when new articles are posted on . Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Treating people in the early stages of diabetes-related eye disease may help slow the progression of the condition, but a new study also suggests that it can’t help prevent vision loss in the future.

The use of anti-vascular endothelial growth factor injections has been linked to an increased risk of mortality in patients with diabetic retinopathy in a new study, sounding a note of caution ...

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

Please provide your email address to receive an email when new articles are posted on . The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third ...

The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol S study was a randomized, active-controlled study comparing Lucentis to a type of laser therapy called panretinal or scatter ...